Novan to Present Berdazimer Gel, 10.3% (SB206) Clinical Data at Annual Meeting of the Society for Investigative Dermatology
19 mai 2022 09h05 HE
|
Novan, Inc.
– Based on clinical data from previously completed B-SIMPLE4 pivotal Phase 3 clinical study, berdazimer gel, 10.3% (SB206) can shorten the duration of molluscum infection and increase the chance of...
Novan Reports First Quarter 2022 Financial Results and Provides Corporate Update
16 mai 2022 06h30 HE
|
Novan, Inc.
– Transformational quarter for Novan, marked by acquisition of EPI Health – – Strongest quarter in total prescriptions for Rhofade increasing 47% from Q1 2021 – – Ongoing activities toward...
Novan to Report First Quarter 2022 Financial Results on May 16, 2022
06 mai 2022 09h00 HE
|
Novan, Inc.
DURHAM, N.C., May 06, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its first quarter 2022 financial results on Monday, May...
Novan to Participate in the Virtual Investor Innovation in Dermatology Spotlight Event
20 avr. 2022 09h05 HE
|
Novan, Inc.
DURHAM, N.C., April 20, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced it will participate in the Virtual Investor Innovation in Dermatology...
Novan Announces Late-Breaking Abstract Accepted for Presentation at American Academy of Dermatology’s (AAD) 2022 Annual Meeting
24 mars 2022 09h00 HE
|
Novan, Inc.
DURHAM, N.C., March 24, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that data from its pivotal Phase 3 study of berdazimer gel 10.3% (SB206) for...
Novan, Inc. to Present at Two Upcoming Investor Conferences
14 mars 2022 09h00 HE
|
Novan, Inc.
DURHAM, N.C., March 14, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that Paula Brown Stafford, President and Chief Executive Officer of Novan,...
Novan Acquires EPI Health, a Specialty Dermatology Company
11 mars 2022 06h35 HE
|
Novan, Inc.
– EPI Health promotes four prescription products posting 2021 operating revenue of $17.6 million – – Acquisition forward integrates Novan with complementary commercial infrastructure to drive...
Novan Reports Full Year 2021 Financial Results and Provides Corporate Update
22 févr. 2022 07h00 HE
|
Novan, Inc.
– First New Drug Application (NDA) submission targeted in Q4 2022 for lead program SB206 (berdazimer gel 10.3%) for molluscum contagiosum – – Ongoing advancement of priority development pipeline...
Novan to Report Full Year 2021 Financial Results on February 22, 2022
15 févr. 2022 09h00 HE
|
Novan, Inc.
DURHAM, N.C., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its full year 2021 financial results on Tuesday, February...
Novan Announces Presentation of Two Posters at the 2022 Winter Clinical Dermatology Conference
14 janv. 2022 09h05 HE
|
Novan, Inc.
DURHAM, N.C., Jan. 14, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that data from the Company’s completed Phase 2 and Phase 3 clinical studies of...